Abivax (NASDAQ:ABVX) Shares Gap Up – Here’s What Happened

Abivax SA Sponsored ADR (NASDAQ:ABVX)’s stock price gapped up prior to trading on Monday . The stock had previously closed at $142.31, but opened at $147.00. Abivax shares last traded at $142.64, with a volume of 285,247 shares traded.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. Barclays assumed coverage on Abivax in a report on Monday, October 13th. They set an “overweight” rating and a $142.00 target price on the stock. Wolfe Research raised Abivax to a “strong-buy” rating in a research note on Thursday, November 6th. Truist Financial set a $140.00 price target on shares of Abivax in a research report on Monday, November 24th. Piper Sandler reissued an “overweight” rating and issued a $142.00 price objective on shares of Abivax in a report on Tuesday, December 16th. Finally, Wall Street Zen downgraded Abivax from a “hold” rating to a “sell” rating in a research report on Saturday, December 13th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Abivax has an average rating of “Moderate Buy” and a consensus price target of $128.73.

Abivax Stock Up 0.4%

The company has a debt-to-equity ratio of 0.03, a quick ratio of 7.86 and a current ratio of 7.86. The firm has a market capitalization of $11.14 billion, a price-to-earnings ratio of -34.21 and a beta of 0.49. The firm has a fifty day moving average price of $113.55 and a 200 day moving average price of $77.08.

Abivax (NASDAQ:ABVX) last issued its quarterly earnings data on Monday, December 15th. The company reported ($2.46) earnings per share (EPS) for the quarter. The company had revenue of ($4.92) million during the quarter. As a group, sell-side analysts expect that Abivax SA Sponsored ADR will post -2.83 EPS for the current fiscal year.

Institutional Investors Weigh In On Abivax

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Kennedy Capital Management LLC boosted its position in shares of Abivax by 7.1% during the second quarter. Kennedy Capital Management LLC now owns 241,188 shares of the company’s stock worth $1,845,000 after buying an additional 15,997 shares during the period. Quadrature Capital Ltd bought a new stake in Abivax during the 2nd quarter valued at $148,000. Octagon Capital Advisors LP acquired a new position in Abivax during the 1st quarter worth $7,688,000. Saturn V Capital Management LP raised its position in shares of Abivax by 12.6% during the 2nd quarter. Saturn V Capital Management LP now owns 622,479 shares of the company’s stock worth $4,762,000 after buying an additional 69,553 shares in the last quarter. Finally, Allostery Investments LP lifted its position in Abivax by 86.0% in the first quarter. Allostery Investments LP now owns 1,099,654 shares of the company’s stock worth $6,873,000 after purchasing an additional 508,401 shares during the period. Hedge funds and other institutional investors own 47.91% of the company’s stock.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.